JP6727210B2 - Ｆｇｆ２１誘導体及びその使用 - Google Patents

Ｆｇｆ２１誘導体及びその使用 Download PDF

Info

Publication number
JP6727210B2
JP6727210B2 JP2017533789A JP2017533789A JP6727210B2 JP 6727210 B2 JP6727210 B2 JP 6727210B2 JP 2017533789 A JP2017533789 A JP 2017533789A JP 2017533789 A JP2017533789 A JP 2017533789A JP 6727210 B2 JP6727210 B2 JP 6727210B2
Authority
JP
Japan
Prior art keywords
ethoxy
amino
fgf21
oxo
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017533789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505146A (ja
JP2018505146A5 (2
Inventor
ビアギト・ヴィツォレク
ティーナ・ムラ・タグモーセ
クリスチャン・サス−ウルム
ビアギッテ・アンデルセン
イェルゲン・オルセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2018505146A publication Critical patent/JP2018505146A/ja
Publication of JP2018505146A5 publication Critical patent/JP2018505146A5/ja
Application granted granted Critical
Publication of JP6727210B2 publication Critical patent/JP6727210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017533789A 2014-12-23 2015-12-22 Ｆｇｆ２１誘導体及びその使用 Active JP6727210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505146A JP2018505146A (ja) 2018-02-22
JP2018505146A5 JP2018505146A5 (2) 2018-11-29
JP6727210B2 true JP6727210B2 (ja) 2020-07-22

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533789A Active JP6727210B2 (ja) 2014-12-23 2015-12-22 Ｆｇｆ２１誘導体及びその使用

Country Status (24)

Country Link
US (3) US9744213B2 (2)
EP (1) EP3236991B1 (2)
JP (1) JP6727210B2 (2)
KR (1) KR102427527B1 (2)
CN (1) CN107108709B (2)
AR (1) AR103246A1 (2)
AU (1) AU2015371056B2 (2)
DK (1) DK3236991T3 (2)
ES (1) ES2742503T3 (2)
HK (1) HK1246156B (2)
HR (1) HRP20191292T1 (2)
HU (1) HUE044783T2 (2)
IL (1) IL252438B (2)
MX (1) MX377044B (2)
MY (1) MY181181A (2)
PL (1) PL3236991T3 (2)
PT (1) PT3236991T (2)
RS (1) RS59154B1 (2)
RU (1) RU2729011C2 (2)
SA (1) SA517381673B1 (2)
SI (1) SI3236991T1 (2)
TW (2) TWI681966B (2)
WO (1) WO2016102562A1 (2)
ZA (1) ZA201703768B (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
IL272987B (en) 2017-09-04 2022-08-01 89Bio Ltd fgf-21 mutant peptide conjugates and uses thereof
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
WO2022238510A1 (en) 2021-05-11 2022-11-17 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
WO2023035817A1 (zh) * 2021-09-08 2023-03-16 北京志道生物科技有限公司 一种fgf21突变蛋白及其应用
IL317317A (en) 2022-07-08 2025-01-01 Novo Nordisk As Highly potent ISVD compounds capable of replacing FVIII(A)
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
KR20250167609A (ko) 2023-03-30 2025-12-01 노보 노르디스크 에이/에스 융합 화합물 및 그 용도
JP7823234B2 (ja) * 2023-05-12 2026-03-03 ノヴォ ノルディスク アー／エス 長時間作用型成長ホルモン受容体拮抗薬およびその使用
WO2025056575A1 (en) 2023-09-11 2025-03-20 Novo Nordisk A/S Anti il-6 domain antibodies
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
BR122019021416A2 (2) 2003-09-19 2019-12-21
EP2270163A1 (en) 2003-12-10 2011-01-05 Eli Lilly and Company Muteins of fibroblast growth factor 21
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
EP2194064A1 (en) * 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CA2572770A1 (en) * 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
KR100854198B1 (ko) 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) * 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
JP2012529463A (ja) 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
US20120035099A1 (en) * 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
MX2014002260A (es) * 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
ES2915851T3 (es) * 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares

Also Published As

Publication number Publication date
AU2015371056A1 (en) 2017-06-15
CN107108709B (zh) 2021-12-14
US9744213B2 (en) 2017-08-29
KR20170095256A (ko) 2017-08-22
HRP20191292T1 (hr) 2019-10-18
TW202012431A (zh) 2020-04-01
TWI681966B (zh) 2020-01-11
US20180140673A1 (en) 2018-05-24
MX2017007458A (es) 2017-08-10
MY181181A (en) 2020-12-21
RU2017125050A3 (2) 2019-06-06
WO2016102562A1 (en) 2016-06-30
EP3236991B1 (en) 2019-06-19
ES2742503T3 (es) 2020-02-14
JP2018505146A (ja) 2018-02-22
BR112017011552A2 (pt) 2018-02-14
CN107108709A (zh) 2017-08-29
ZA201703768B (en) 2020-05-27
TW201632545A (zh) 2016-09-16
AR103246A1 (es) 2017-04-26
IL252438B (en) 2021-09-30
US9895417B2 (en) 2018-02-20
RU2017125050A (ru) 2019-01-25
HK1246156B (en) 2020-03-27
HUE044783T2 (hu) 2019-11-28
US20170354713A1 (en) 2017-12-14
RU2729011C2 (ru) 2020-08-03
TWI708781B (zh) 2020-11-01
AU2015371056B2 (en) 2020-06-25
US20170182124A1 (en) 2017-06-29
US10124039B2 (en) 2018-11-13
RS59154B1 (sr) 2019-10-31
KR102427527B1 (ko) 2022-08-01
IL252438A0 (en) 2017-07-31
EP3236991A1 (en) 2017-11-01
DK3236991T3 (da) 2019-08-26
MX377044B (es) 2025-03-07
SI3236991T1 (sl) 2019-09-30
PT3236991T (pt) 2019-09-06
SA517381673B1 (ar) 2020-10-29
CA2972128A1 (en) 2016-06-30
PL3236991T3 (pl) 2019-12-31

Similar Documents

Publication Publication Date Title
JP6727210B2 (ja) Ｆｇｆ２１誘導体及びその使用
HK1246156A1 (en) Fgf21 derivatives and uses thereof
ES2692495T3 (es) Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
JP5875527B2 (ja) ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン
ES2328579T3 (es) Derivados de insulina de larga duracion y procedimientos asociados.
ES2831848T3 (es) Análogo de insulina humana A22K, desB27, B29R, desB30, acilado en la posición épsilon de la lisina 22
JP6949832B2 (ja) タンパク質コンジュゲート
JP2012529463A (ja) ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
JP2013533227A (ja) Ｆｇｆ２１類似体および誘導体
WO2017220706A1 (en) Pharmaceutical compositions of fgf21 derivatives and uses thereof
US20140357838A1 (en) N-Terminally Modified Insulin Derivatives
CA2972128C (en) Fgf21 derivatives and uses thereof
JP2019501963A (ja) アミリンおよびアミリンミメティック化合物の非凝集性バイオコンジュゲート、それを含む組成物、ならびにその製造および使用
BR112017011552B1 (pt) Derivados de uma proteína do fgf21 e uso terapêutico e/ou profilático dos mesmos
TW202613157A (zh) 一種多肽激動劑，其製備方法及醫藥用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200630

R150 Certificate of patent or registration of utility model

Ref document number: 6727210

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250